ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/09/2024 BST			5-day change	1st Jan Change
300.00 ^USD	+0.10%		-0.83%	+5.98%

09-10	Transcript : ICON Public Limited Company Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 03:45 PM
08-14	ICON Names Nigel Clerkin as CFO	DJ

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about ICON Public Limited Company

Transcript : ICON Public Limited Company Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 03:45 PM	09-10
ICON Names Nigel Clerkin as CFO	08-14	DJ
ICON Appoints New Chief Financial Officer	08-14	MT
ICON plc Announces Chief Financial Officer Changes	08-14	CI
Truist Adjusts Price Target on ICON to $383 From $367, Maintains Buy Rating	07-26	MT
Tranche Update on ICON Public Limited Company's Equity Buyback Plan announced on February 21, 2024.	07-25	CI
Transcript : ICON Public Limited Company, Q2 2024 Earnings Call, Jul 25, 2024	07-25
ICON Q2 Adjusted EPS, Revenue Rise; 2024 Outlook Updated -- Shares Drop After Hours	07-24	MT
Earnings Flash (ICLR) ICON Reports Q2 EPS $3.75, vs. Street Est of $3.67	07-24	MT
ICON Public Limited Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-24	CI
ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024	07-24	CI
ICON Public Limited Company Announces Board Changes	07-24	CI
Transcript : ICON Public Limited Company Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 01:30 PM	06-06
Baird Adjusts Price Target on ICON to $367 From $363, Maintains Outperform Rating	05-31	MT
Transcript : ICON Public Limited Company - Analyst/Investor Day	05-30
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024	05-30	CI
Diamyd Medical AB Appoints ICON plc to Conduct Interim Analysis for the Phase 3 Trial	05-16	CI
ICON Prices $2 Billion Debt Offering	04-30	MT
ICON Public Limited Company Announces Pricing of USD 2 Billion Notes	04-30	CI
UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating	04-26	MT
ICON Seeks M&A	04-25	CI
Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024	04-25
ICON Public Limited Company acquired HumanFirst, Inc. for $13.3 million.	04-24	CI
ICON Q1 Adjusted EPS, Revenue Rise, 2024 Guidance Range Narrowed	04-24	MT
Earnings Flash (ICLR) ICON Reports Q1 EPS $3.47, vs. Street Est of $3.41	04-24	MT

Chart ICON Public Limited Company

Duration

Period

More charts

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

41,100

Sector

Biotechnology & Medical Research

Calendar

22/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company